Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action.
Alessandro Larcher, Isaline Rowe, Federico Belladelli...
https://pubmed.ncbi.nlm.nih.gov/34783716/Actively Recruiting
Led by Joshua Mann, MPH · Updated on 2024-04-26
10000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are collecting detailed information from patients with Von Hippel-Lindau Disease VHL and related genetic conditions such as Birt-Hogg-Dube Syndrome, Hereditary Leiomyomatosis and Renal Cell Cancer, and SDHB Gene Mutation. This observational study aims to build a large database called MyVHL to understand how lifestyle, medications, and other factors affect these rare conditions and the quality of life of those affected. Due to the rarity of these diseases, this study helps identify patterns that may influence tumor growth or disease progression. Participants contribute data about their health, including information on tumors in various organs such as the central nervous system, kidneys, adrenal glands, retina, thyroid, ears, pancreas, lungs, liver, and skin. The study collects information on the number and size of these tumors as related to specific genetic mutations. This data gathering continues on average for about one year through the studys completion. During the study, participants provide ongoing health information which researchers use to track tumor development and other disease-related changes. This helps researchers gain insights into disease patterns and potential risk factors. The study includes all patients with VHL and related conditions, and participation involves sharing health data over time. The study is observational and does not include treatments, focusing instead on understanding the natural history of these rare diseases.
CONDITIONS
MyVHL: Patient Natural History Study
J
Joshua Mann, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Joshua Mann, MPH
Lead Sponsor
National Organization for Rare Disorders
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 1 year
Participants are monitored to observe the number and size of various tumors and lesions related to VHL and other genetic mutations.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Alessandro Larcher, Isaline Rowe, Federico Belladelli...
https://pubmed.ncbi.nlm.nih.gov/34783716/Joshua Mann, MPH
Lead Sponsor
National Organization for Rare Disorders
Collaborating Sponsor